We have located links that may give you full text access.
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
A First Report on [ 18 F]FPRGD 2 PET/CT Imaging in Multiple Myeloma.
An observational study was set up to assess the feasibility of [18 F]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [18 F]NaF/[18 F]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [18 F]FPRGD2 . The obtained images were compared with results of low dose CT and already available results of a combined [18 F]NaF/[18 F]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [18 F]FPRGD2 PET/CT compared to low dose CT (98%) or [18 F]NaF/[18 F]FDG PET/CT (70%) and all FLs detected with [18 F]FPRGD2 PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [18 F]FPRGD2 positive lesions were seen than [18 F]NaF/[18 F]FDG positive lesions. This study suggests that [18 F]FPRGD2 PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [18 F]FPRGD2 uptake were already detected with CT alone.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app